Notably, its active component, mycophenolic acid, at clinical concentrations, can upregulate p53 expression, induce S-phase arrest in HCC cells, and downregulate VEGF to inhibit tumor angiogenesis, demonstrating potential antitumor effects [69]. Here, VEGFA is linked to neoplasm.